FATE - Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29 revenue of $44.34M beats by $25.93M
- Fate Therapeutics press release ( NASDAQ: FATE ): Q4 GAAP EPS of -$0.58 beats by $0.29 .
- Revenue of $44.34M (+159.8% Y/Y) beats by $25.93M .
- Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables
For further details see:
Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93M